sellWeak10b5-1 plan
Christopher Krawtschuk sold $20k of BLUE
Chief Financial Officer at bluebird bio, Inc.. 4,526 shares at an average of $4.52, traded Dec 6, 2023, filed Dec 8, 2023.
Warning score
2Value
$20k
4,526 shares
Holdings after
45,474
-9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$20k at market
- 0Share of holdings soldSold 9.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-23-008250, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 6, 2023 | SOpen-market sale Common Stock10b5-1 | -4,526 | $4.52 | $20k | 45,474 | Dec 8, 2023 |
Related signals
Other insiders at bluebird bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $2,289 584 shares | -7% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $1,960 500 shares | -6% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $473 64 shares | -1% | |
| 3Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $902 122 shares | -1% | |
| 0Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $176 19 shares | -0% | |
| 3Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $1,178 2,824 shares | -2% | |
| 13Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $405 971 shares | -0% | |
| 10Weak | bluebird bio, Inc. | Richard A Colvin Chief Medical Officer | $10k 6,770 shares | -5% | |
| 10Weak | bluebird bio, Inc. | Thomas J Klima See Remarks | $6,986 4,573 shares | -4% | |
| 20Weak | bluebird bio, Inc. | Andrew Obenshain President and CEO | $9,311 6,095 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.